35:57

FCS unmasked: Closing Gaps in diagnosis, treatment and patient support

36:48

Effective lifespan care in sickle cell disease: From recognizing the burden to novel therapeutics

34:15

Applying patient and disease characteristics to guide R/M NPC treatment

37:19

Bridging the diagnostic and therapeutic gaps in Fabry disease management

36:06

Therapeutic advances in RRMM: What is the latest on practical application of BCMA-directed therapies

39:05

Phacoemulsification in cataract surgery: Evolving options to optimize refractive outcomes

31:47

Stargardt disease: Improving awareness, diagnosis, and patient support

36:36

A case-based discussion on PAH: Early detection, risk stratification and treatment decision-making

27:25

Mastering DKA management: From pathophysiology to prevention and ketone monitoring strategies

26:05

Continuous glucose monitoring for cardiovascular risk reduction: Next frontier in preventive care

33:12

HER2 as a targetable biomarker in gastrointestinal oncology

42:29

Navigating the evolving role of immunotherapy in advanced endometrial carcinoma

17:41

Focus on treatment advances for ATTRv: A heterogeneous, debilitating & ultimately fatal disease

15:38

Advancing care for patients with infantile hemangioma: Timing is key

01:08:45

Navigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025

39:11

Accelerating myasthenia gravis diagnosis and treatment: Practical strategies & therapeutic advances

34:52

Incorporating ADCs into the treatment of mBC: Practical considerations for the community oncologist

33:38

Multidisciplinary management of TNBC: Integrating immunotherapies for early and metastatic disease

34:29

Personalised care for people living with HIV: Supporting open dialogue & informed treatment choices

15:23

Applying immunotherapy in clinical practice for patients with early stage NSCLC

13:50

RET-positive NSCLC: Translating insights into targeted approaches

35:47

Advances in dry eye disease: From diagnosis to new treatment targets

34:25

Recent advances in the care of patients with geographic atrophy: Exploring new & emerging therapies

29:19

Reducing burden of disease in gMG: Exploring the role of FcRn inhibitors

12:02

The potential of BTKi therapies in progressive forms of MS

32:32

Empowering T2D management: The evolution of basal insulin therapy

56:43

Navigating the clinical impact of TROP2-targeting in NSCLC

37:52

The evolving standard of care for advanced/recurrent endometrial cancer

34:42

Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia

33:29

touchMDT ADCs in metastatic breast cancer: Managing toxicities and optimizing quality of life

17:43

Precision in practice: Adopting emerging therapies for retinal diseases to reduce burden of disease

36:13

PARP inhibitors for metastatic castration-resistant prostate cancer

30:15

The next frontier in managing obesity with or without T2D: The role of novel combinations

35:15

Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals

15:41

Looking to the future in the treatment of steroid-refractory chronic GvHD

54:39

Updates in BCMA-directed therapies in multiple myeloma from ASH 2024

29:09

RAS mutations and personalized cancer care: Targeting the future

20:25

Focused insights: Data implications of ADCs in NSCLC treatment

01:19:57

Collaboration in chronic ITP: Improving quality of life and patient outcomes

35:50

Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life

32:34

Navigating treatment choices in high-risk early-stage melanoma

35:54

Advancing the treatment of muscle-invasive bladder cancer

17:50

Supporting healing in epidermolysis bullosa: Innovations and new directions for care

33:48

Primary biliary cholangitis: Appraising the changing therapeutic landscape

39:16

Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors

27:29

Precision targeting of MET in NSCLC: A multidisciplinary approach

32:03

Vaccination strategies for pneumococcal disease: Update and perspectives on clinical need and impact

50:02

Optimizing treatment of CML in the first-line setting and beyond

33:26

Pharmacological management of agitation in Alzheimer’s dementia

51:13

Multidisciplinary insights:Navigating the challenges of systemic mastocytosis diagnosis & management

55:13

Precision targeting of MET in NSCLC: A multidisciplinary approach

55:22

Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024

38:00

Navigating the management of cholestatic pruritus in patients with PBC

31:44

Innovations in glaucoma care: Targeting pathophysiology to expand treatment options

39:00

Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts

40:57

Expanding HER2 horizons: Implications for NSCLC and beyond

31:53

Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease

17:24

Updates in recurrent/metastatic nasopharyngeal carcinoma: The role of immune checkpoint inhibitors

51:31

Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?

40:30

Continuous glucose monitoring in type 2 diabetes: Overcoming barriers to optimize outcomes